ANKRD30BL

Across TCGA pan-cancer cohorts, ANKRD30BL RNA is linked to patient survival in 16 of 34 cancer types, making it the most broadly survival-associated ANKRD30BL data layer compared with 4 for mutation status.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ANKRD30BL RNA is associated with worse overall survival. In most high-consensus cancer types, elevated ANKRD30BL expression acts as an unfavorable survival marker, although some lineages such as LGG and UCS show a favorable association.

LIHC, KIRC, and LGG are the cancer types where ANKRD30BL RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	All	0.344	0.712	<.001	45	view →
KIRC	OS	Quartile	All	0.492	0.667	.002	33	view →
LGG	OS	Tertile	All	0.920	0.836	<.001	24	view →
ACC	OS	Tertile	II,III,IV	0.579	0.903	.016	21	view →
KICH	OS	Tertile	III,IV	0.178	0.847	<.001	18	view →
UVM	OS	Median	All	0.474	0.843	.012	14	view →
UCS	DFS	Median	II,III,IV	0.431	0.169	.033	14	view →
ESCA	DFS	Quartile	III,IV	0.615	0.306	.009	12	view →
PCPG	DFS	Tertile	All	0.865	0.944	.034	7	view →
READ	OS	Tertile	III,IV	0.397	0.726	.040	6	view →
CESC	OS	Tertile	All	0.793	0.518	.043	6	view →
STAD	DFS	Quartile	IV	1.000	0.407	.037	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 16 lineages.

ANKRD30BL–LIHC (OS)

Open the LIHC breakdown →